Clinical insights: The shift from IV to Subcutaneous Infliximab
הרצאתה של פרופ' אפרת ברוידא, המכון לגסטרואנטרולוגיה, מרכז רפואי שמיר
כל הפוסטים בArticle
Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease
16:53
הרצאתו של Professor Peter Irving, Guy’s and St Thomas’ Hospital London, King's College London, UK
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study
9:21
Buisson A et.al.; Aliment Pharmacol Ther. 2024 Feb;59(4):526-534
Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease
12:49
Roblin X et.al.; J Crohns Colitis. 2023 Nov 2:jjad188
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
9:24
Smith PJ et.al.; Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1143-1156.
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
9:28
Constantin A et.al.; Rheumatology (Oxford). 2023 Aug 1;62(8):2838-2844
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
15:04
D’Haens et.al.; Clinical Drug Investigation 2023 Apr;43(4):277-288
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
14:58
Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
14:54
Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
15:11
Peyrin‑Biroulet et.al.; BMC Gastroenterology 2022 Jun 8;22(1):291